Drug Repurposing Service Providers Market, 2020-2030

1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines

3.1. Chapter Overview
3.2. Overview of Drug Repurposing
3.2.1 History of Drug Repurposing
3.2.2 Strategies for Drug Repurposing
3.3. Repurposing versus the Traditional Drug Discovery
3.4. Benefits and Challenges Associated with Drug Repurposing
3.5. Drug Repurposing Service Providers

4.1. Chapter Overview
4.2. Drug Repurposing Service Provider: Overall Market Landscape of Contract Research Organizations (CROs)
4.2.1. Analysis by Year of Establishment
4.2.2. Analysis by Company Size
4.2.3. Analysis by Location of Headquarters
4.2.4. Analysis by Company Size and Location of Headquarters
4.2.5. Analysis by Technology Specifications
4.2.6. Analysis by Type of Drug Molecule
4.2.7. Analysis by Status of Drug
4.2.8. Analysis by Repurposing Approach
4.2.9. Analysis by Services Offered
4.3. Drug Repurposing Service Provider: Overall Market Landscape of Big Data/Analytics Service Providers
4.3.1. Analysis by Year of Establishment
4.3.2. Analysis by Company Size
4.3.3. Analysis by Location of Headquarters
4.3.4. Analysis by Company Size and Location of Headquarters
4.3.5. Analysis by Technology Specifications
4.3.6. Analysis by Type of Drug Molecule
4.3.7. Analysis by Status of Drug
4.3.8. Analysis by Repurposing Approach
4.3.9. Analysis by Services Offered
4.4. Drug Repurposing Service Provider: Overall Market Landscape of Technology Providers
4.4.1. Analysis by Year of Establishment
4.4.2. Analysis by Company Size
4.4.3. Analysis by Location of Headquarters
4.4.4. Analysis by Company Size and Location of Headquarters
4.4.5. Analysis by Technology Specifications
4.4.6. Analysis by Type of Drug Molecule
4.4.7. Analysis by Status of Drug
4.4.8. Analysis by Repurposing Approach
4.2.9. Analysis by Services Offered

5.1. Chapter Overview
5.2. Drug Repurposing Service Providers: List of Non-Profit Organizations
5.3. Stakeholder Profiles
5.3.1. Cures Within Reach
5.3.2. GlobalCures
5.3.3. Anticancer Fund
5.3.4. National Center for Advancing Translational Sciences
5.4. Drug Repurposing Service Providers: List of Academic Organizations

6.1. Chapter Overview
6.2. Company Profiles for CROs
6.2.1 Auxiliis Pharma
6.2.1.1. Company Overview
6.2.1.2. Service Portfolio
6.2.1.3. Future Outlook
6.2.2. ChemBio Discovery Solutions
6.2.2.1. Company Overview
6.2.2.2. Service Portfolio
6.2.2.3. Future Outlook
6.2.3. GVK BIO
6.2.3.1. Company Overview
6.2.3.2. Technology Overview
6.2.3.3. Service Portfolio
6.2.3.4. Future Outlook
6.2.4. Iris Pharma
6.2.4.1. Company Overview
6.2.4.2. Service Portfolio
6.2.4.3. Future Outlook
6.2.5. Physiogenex
6.2.5.1. Company Overview
6.2.5.2. Service Portfolio
6.2.5.3. Future Outlook
6.3. Company Profiles for Big Data/Analytics Service Providers
6.3.1. Excelra
6.3.1.1. Company Overview
6.3.1.2. Technology Overview
6.3.1.3. Service Portfolio
6.3.1.4. Future Outlook
6.3.2. Smart Pharma
6.3.2.1. Company Overview
6.3.2.2. Technology Overview
6.3.2.3. Service Portfolio
6.3.2.4. Future Outlook
6.4. Company Profiles for Technology Providers
6.4.1. Lantern Pharma
6.4.1.1. Company Overview
6.4.1.2. Technology Overview
6.4.1.3. Service Portfolio
6.4.1.4. Future Outlook
6.4.2. Panxome
6.4.2.1. Company Overview
6.4.2.2. Technology Overview
6.4.2.3. Service Portfolio
6.4.2.4. Future Outlook
6.4.3. Pharmacelera
6.4.3.1. Company Overview
6.4.3.2. Technology Overview
6.4.3.3. Service Portfolio
6.4.3.4. Future Outlook
6.4.4. Socium
6.4.4.1. Company Overview
6.4.4.2. Service Portfolio
6.4.4.3. Future Outlook
6.4.5. SOM Biotech
6.4.5.1. Company Overview
6.4.5.2. Technology Overview
6.4.5.3. Service Portfolio
6.4.5.4. Future Outlook

7.1. Chapter Overview
7.2. Partnership Models
7.3. Drug Repurposing Service Providers: List of Partnerships
7.3.1. Analysis by Year of Partnership
7.3.2. Analysis by Type of Partnership
7.3.3. Analysis by Year and Type of Partnership
7.3.4. Analysis by Type of Technology/Platform Used
7.3.5. Analysis by Therapeutic Area
7.3.6. Geographical Analysis
7.3.6.1. Continent-wise Distribution
7.3.6.2. Country-wise Distribution

8.1. Chapter Overview
8.2. List of Drug Repurposing Initiatives of Big Pharma Players
8.2.1. Analysis by Number of Initiatives
8.2.2. Analysis by Year of Initiative
8.2.3. Analysis by Type of Initiative
8.2.4. Analysis by Therapeutic Area
8.2.5. Analysis by Type of Drug Molecule
8.2.6. Big Pharma Activity: Analysis by Year of Initiative and Company
8.2.7. Big Pharma Activity: Analysis by Type of Drug Molecule and Company
8.3. Competitive Benchmarking of Big Pharma Players
8.3.1. Big Pharma Investment Summary
8.4. Initiatives Undertaken by Leading Players
8.4.1. Initiatives Undertaken by AbbVie
8.4.1.1 In-House Initiatives
8.4.2. Initiatives Undertaken by Astellas Pharma
8.4.2.1. Initiatives in Collaboration with Other Stakeholders
8.4.2.2 Recent Regulatory Approvals of Repurposed Drugs
8.4.3. Initiatives Undertaken By AstraZeneca
8.4.3.1. In-House Initiatives
8.4.3.2 Initiatives in Collaboration with Other Stakeholders
8.4.4. Initiatives Undertaken by Bayer
8.4.4.1. Initiatives in Collaboration with Other Stakeholders
8.4.5. Initiatives Undertaken by Boehringer Ingelheim
8.4.5.1. Initiatives in Collaboration with Other Stakeholders
8.4.5.2 Recent Regulatory Approvals of Repurposed Drugs
8.4.6. Initiatives Undertaken by Eli Lilly
8.4.6.1. Initiatives in Collaboration with Other Stakeholders
8.4.6.2 Recent Regulatory Approvals of Repurposed Drugs
8.4.7. Initiatives Undertaken by Gilead Sciences
8.4.7.1 Recent Regulatory Approvals of Repurposed Drugs
8.4.8. Initiatives Undertaken by GSK
8.4.8.1. In-House Initiatives
8.4.8.2 Initiatives in Collaboration with Other Stakeholders
8.4.9. Initiatives Undertaken by Novartis
8.4.9.1. In-House Initiatives
8.4.9.2 Initiatives in Collaboration with Other Stakeholders
8.4.9.3 Recent Regulatory Approvals of Repurposed Drugs
8.4.10. Initiatives Undertaken by Roche
8.4.10.1. In-House Initiatives
8.4.10.2 Initiatives in Collaboration with Other Stakeholders
8.4.11. Initiatives Undertaken by Sanofi
8.4.11.1 In-House Initiatives
8.4.11.2. Recent Regulatory Approvals of Repurposed Drugs
8.5. Other Big Pharma Players
8.5.1. Initiatives Undertaken by Pfizer
8.5.1.1. Initiatives in Collaboration with Other Stakeholders

9.1. Chapter Overview
9.2. Scope and Methodology
9.3. Drug Repurposing: Discontinued Clinical Trials
9.3.1. Analysis by Trial Status
9.3.2. Analysis by Trial Phase
9.3.3. Analysis by Cause of Discontinuation of Clinical Research
9.3.4. Analysis by Therapeutic Area
9.3.5. Analysis by Location of Trial Site
9.3.6. Analysis by Phase Distribution versus Cause of Discontinuation of Clinical Research
9.3.7. Analysis by Trial Phase and Key Therapeutic Area
9.3.8. Analysis by Cause of Discontinuation of Clinical Research and Key Therapeutic Area
9.4. Discontinued Clinical Trials: Key Therapeutic Area
9.4.1. Discontinued Clinical Trials: Oncology Disorders
9.4.1.1. Analysis by Trial Status
9.4.1.2. Analysis by Trial Status
9.4.1.3. Analysis by Cause of Discontinuation of Clinical Research
9.4.1.4. Analysis by Location of Trial Site
9.4.2. Discontinued Clinical Trials: CNS Disorders
9.4.2.1. Analysis by Trial Status
9.4.2.2. Analysis by Trial Status
9.4.2.3. Analysis by Cause of Discontinuation of Clinical Research
9.4.2.4. Analysis by Location of Trial Site
9.4.3. Discontinued Clinical Trials: Metabolic Disorders
9.4.3.1. Analysis by Trial Status
9.4.3.2. Analysis by Trial Status
9.4.3.3. Analysis by Cause of Discontinuation of Clinical Research
9.4.3.4. Analysis by Location of Trial Site
9.4.4. Discontinued Clinical Trials: Infectious Disorders
9.4.4.1. Analysis by Trial Status
9.4.4.2. Analysis by Trial Phase
9.4.4.3. Analysis by Cause of Discontinuation of Clinical Research
9.4.4.4. Analysis by Location of Trial Site
9.4.5. Discontinued Clinical Trials: Autoimmune Disorders
9.4.5.1. Analysis by Trial Status
9.4.5.2. Analysis by Trial Phase
9.4.5.3. Analysis by Cause of Discontinuation of Clinical Research
9.4.5.4. Analysis by Location of Trial Site
9.5. List of Potential Drug Candidates

10.1. Chapter Overview
10.2. Key Assumptions
10.3. Methodology
10.4. Overall Cost Saving Potential of Repurposed Drugs, 2020-2030
10.5. Concluding Remarks

11.1. Chapter Overview
11.2. Key Assumptions and Forecast Methodology
11.3. Overall Drug Repurposing Services Market, 2020-2030
11.4. Drug Repurposing Services Market: Distribution by Type of Drug Molecule, 2020-2030
11.4.1. Drug Repurposing Services Market for Small Molecules, 2020-2030
11.4.2. Drug Repurposing Services Market for Biologics, 2020-2030
11.5. Drug Repurposing Services Market: Distribution by Therapeutic Area, 2020-2030
11.5.1. Drug Repurposing Services Market for Same Therapeutic Area, 2020-2030
11.5.2. Drug Repurposing Services Market for Different Therapeutic Area, 2020-2030
11.6. Drug Repurposing Services Market: Distribution by Company Size, 2020-2030
11.6.1. Drug Repurposing Services Market for Small Companies, 2020-2030
11.6.2. Drug Repurposing Services Market for Mid-Sized Companies, 2020-2030
11.6.3. Drug Repurposing Services Market for Large and Very Large Companies, 2020-2030
11.7. Drug Repurposing Services Market: Distribution by Geography, 2020, 2025 and 2030
11.7.1. Drug Repurposing Services Market in North America, 2020-2030
11.7.2. Drug Repurposing Services Market in Europe, 2020-2030
11.7.3. Drug Repurposing Services Market in Asia Pacific, 2020-2030

12.1. Chapter Overview
12.2. Current opinions and recuperative initiatives of key players
12.2.1. Biovista
12.2.2. Evotec
12.2.3. Excelra
12.2.4. GVK Bio
12.3. Recuperative strategies for service providers businesses
12.3.1. Strategies for implementation in the short/mid term
12.3.2. Strategies for implementation in the long term

13.1. Chapter Overview
13.2. Shift from One-Time Contracts to Strategic Partnerships
13.3. Adoption of New and Innovative Technologies
13.3.1. Artificial Intelligence
13.3.2. Next Generation Drug Repurposing Techniques
13.4. Focus on Niche Therapeutic Areas
13.5. Increase in Financial Inflow and Outsourcing Budgets

14.1. Chapter Overview
14.2. Nandu Gattu (Senior Vice President, Excelra)

Figure 3.1 History of Drug Repurposing
Figure 3.2 Different Types of Computational Methods Used for Drug Repurposing
Figure 3.3 Schematic Representation of Traditional versus Repurposing Approaches for Drug Discovery
Figure 3.4 Benefits of Drug Repurposing
Figure 3.5 Challenges Associated with Drug Repurposing
Figure 3.6 Types of Drug Repurposing Service Providers
Figure 4.1 Drug Repurposing Service Providers: Distribution by Type of Company
Figure 4.2 Drug Repurposing Service Providers: Distribution by Type of Company, Year of Establishment and Location of Headquarters
Figure 4.3 Drug Repurposing CROs: Distribution by Year of Establishment
Figure 4.4 Drug Repurposing CROs: Distribution by Company Size
Figure 4.5 Drug Repurposing CROs: Distribution by Location of Headquarters
Figure 4.6 Drug Repurposing CROs: Distribution by Company Size and Location of Headquarters
Figure 4.7 Drug Repurposing CROs: Distribution by Technology Specifications
Figure 4.8 Drug Repurposing CROs: Distribution by Type of Drug Molecule
Figure 4.9 Drug Repurposing CROs: Distribution by Status of Drug
Figure 4.10 Drug Repurposing CROs: Distribution by Repurposing Approach
Figure 4.11 Drug Repurposing CROs: Distribution by Types of Services Offered
Figure 4.12 Drug Repurposing Big Data/Analytics Service Providers: Distribution by Company Size
Figure 4.13 Drug Repurposing Big Data/Analytics Service Providers: Distribution by Location of Headquarters
Figure 4.14 Drug Repurposing Big Data/Analytics Service Providers: Distribution by Company Size and Location of Headquarters
Figure 4.15 Drug Repurposing Big Data/Analytics Service Providers: Distribution by Technology Specifications
Figure 4.16 Drug Repurposing Big Data/Analytics Service Providers: Distribution by Type of Drug Molecule
Figure 4.17 Drug Repurposing Big Data/Analytics Service Providers: Distribution by Status of Drug
Figure 4.18 Drug Repurposing Big Data/Analytics Service Providers: Distribution by Repurposing Approach
Figure 4.19 Drug Repurposing Big Data/Analytics Service Providers: Distribution by Types of Services Offered
Figure 4.20 Drug Repurposing Technology Providers: Distribution by Year of Establishment
Figure 4.21 Drug Repurposing Technology Providers: Distribution by Company Size
Figure 4.22 Drug Repurposing Technology Providers: Distribution by Location of Headquarters
Figure 4.23 Drug Repurposing Technology Providers: Distribution by Company Size and Location of Headquarters
Figure 4.24 Drug Repurposing Technology Providers: Distribution by Technology Specifications
Figure 4.25 Drug Repurposing Technology Providers: Distribution by Type of Drug Molecule
Figure 4.26 Drug Repurposing Technology Providers: Distribution by Status of Drug
Figure 4.27 Drug Repurposing Technology Providers: Distribution by Repurposing Approach
Figure 4.28 Drug Repurposing Technology Providers: Distribution by Types of Services Offered
Figure 6.1 Auxiliis Pharma: Service Portfolio
Figure 6.2 ChemBio Discovery Solutions: Service Portfolio
Figure 6.3 GVK Bio: Service Portfolio
Figure 6.4 Iris Pharma: Service Portfolio
Figure 6.5 Physiogenex: Service Portfolio
Figure 6.6 Excelra: Service Portfolio
Figure 6.7 Smart Pharma: Service Portfolio
Figure 6.8 Lantern Pharma: Service Portfolio
Figure 6.9 Panxome: Service Portfolio
Figure 6.10 Pharmacelera: Service Portfolio
Figure 6.11 Socium: Service Portfolio
Figure 6.12 SOM Biotech: Service Portfolio
Figure 7.1 Drug Repurposing Service Providers: Cumulative Distribution by Year of Partnership, Pre-2015-2020
Figure 7.2 Drug Repurposing Service Providers: Distribution by Type of Partnership
Figure 7.3 Drug Repurposing Service Providers: Distribution by Year and Type of Partnership
Figure 7.4 Drug Repurposing Service Providers: Distribution by Type of Technology/Platform Used
Figure 7.5 Drug Repurposing Service Providers: Distribution by Therapeutic Area
Figure 7.6 Drug Repurposing Service Providers: Continent-wise Distribution
Figure 7.7 Drug Repurposing Service Providers: Country-wise Distribution
Figure 8.1 Big Pharma Players: Distribution by Number of Drug Repurposing Initiatives, 2011-2020
Figure 8.2 Big Pharma Players: Cumulative Distribution by Year of Initiative
Figure 8.3 Big Pharma Players: Distribution by Type of Initiative
Figure 8.4 Big Pharma Players: Distribution by Therapeutic Area
Figure 8.5 Big Pharma Players: Distribution by Type of Drug Molecule
Figure 8.6 Big Pharma Activity: Distribution by Year of Initiative and Company
Figure 8.7 Big Pharma Activity: Distribution by Type of Drug Molecule and Company
Figure 8.8 Big Pharma Investment Summary
Figure 9.1 Discontinued Clinical Trials: Distribution by Trial Status
Figure 9.2 Discontinued Clinical Trials: Distribution by Trial Phase
Figure 9.3 Discontinued Clinical Trials: Distribution by Cause of Discontinuation of Clinical Research
Figure 9.4 Discontinued Clinical Trials: Distribution by Therapeutic Area
Figure 9.5 Discontinued Clinical Trials: Distribution by Location of Trial Site
Figure 9.6 Discontinued Clinical Trials: Distribution by Phase versus Cause of Discontinuation of Clinical Research
Figure 9.7 Discontinued Clinical Trials: Distribution by Trial Phase and Key Therapeutic Area
Figure 9.8 Discontinued Clinical Trials: Distribution by Cause of Discontinuation of Clinical Research and Key Therapeutic Area
Figure 9.9 Discontinued Clinical Trials: Distribution by Trial Status for Oncology Disorders
Figure 9.10 Discontinued Clinical Trials: Distribution by Trial Phase for Oncology Disorders
Figure 9.11 Discontinued Clinical Trials: Distribution by Cause of Discontinuation of Clinical Research for Oncology Disorders
Figure 9.12 Discontinued Clinical Trials: Distribution by Location of Trial Site for Oncology Disorders
Figure 9.13 Discontinued Clinical Trials: Distribution by Trial Status for CNS Disorders
Figure 9.14 Discontinued Clinical Trials: Distribution by Trial Phase for CNS Disorders
Figure 9.15 Discontinued Clinical Trials: Distribution by Cause of Discontinuation of Clinical Research for CNS Disorders
Figure 9.16 Discontinued Clinical Trials: Distribution by Location of Trial Site for CNS Disorders
Figure 9.17 Discontinued Clinical Trials: Distribution by Trial Status for Metabolic Disorders
Figure 9.18 Discontinued Clinical Trials: Distribution by Trial Phase for Metabolic Disorders
Figure 9.19 Discontinued Clinical Trials: Distribution by Cause of Discontinuation of Clinical Research for Metabolic Disorders
Figure 9.20 Discontinued Clinical Trials: Distribution by Location of Trial Site for Metabolic Disorders
Figure 9.21 Discontinued Clinical Trials: Distribution by Trial Status for Infectious Disorders
Figure 9.22 Discontinued Clinical Trials: Distribution by Trial Phase for Infectious Disorders
Figure 9.23 Discontinued Clinical Trials: Distribution by Cause of Discontinuation of Clinical Research for Infectious Disorders
Figure 9.24 Discontinued Clinical Trials: Distribution by Location of Trial Site for Infectious Disorders
Figure 9.25 Discontinued Clinical Trials: Distribution by Trial Status for Autoimmune Disorders
Figure 9.26 Discontinued Clinical Trials: Distribution by Trial Phase for Autoimmune Disorders
Figure 9.27 Discontinued Clinical Trials: Distribution by Cause of Discontinuation of Clinical Research for Autoimmune Disorders
Figure 9.28 Discontinued Clinical Trials: Distribution by Location of Trial Site for Autoimmune Disorders
Figure 10.1 Overall Cost Saving Potential of Repurposed Drugs, 2020-2030 (USD Billion)
Figure 11.1 Overall Drug Repurposing Services Market, Base Scenario, 2020-2030 (USD Million)
Figure 11.2 Drug Repurposing Services Market: Distribution by Type of Drug Molecule, Base Scenario, 2020-2030 (%)
Figure 11.3 Drug Repurposing Services Market for Small Molecules, Base Scenario, 2020-2030 (USD Million)
Figure 11.4 Drug Repurposing Services Market for Biologics, Base Scenario, 2020-2030 (USD Million)
Figure 11.5 Drug Repurposing Services Market: Distribution by Therapeutic Area, 2020, 2025 and 2030 (%)
Figure 11.6 Drug Repurposing Services Market for Same Therapeutic Area, Base Scenario, 2020-2030 (USD Million)
Figure 11.7 Drug Repurposing Services Market for Different Therapeutic Area, Base Scenario, 2020-2030 (USD Million)
Figure 11.8 Drug Repurposing Services Market: Distribution by Company Size, Base Scenario, 2020-2030 (%)
Figure 11.9 Drug Repurposing Services Market for Small Companies, Base Scenario, 2020-2030 (USD Million)
Figure 11.10 Drug Repurposing Outsourcing Market for Mid-Sized Companies, Base Scenario, 2020-2030 (USD Million)
Figure 11.11 Drug Repurposing Outsourcing Market for Large and Very Large Companies, Base Scenario, 2020-2030 (USD Million)
Figure 11.12 Drug Repurposing Outsourcing Market: Distribution by Geography, 2020, 2025 and 2030 (%)
Figure 11.13 Drug Repurposing Outsourcing Market in North America, Base Scenario, 2020-2030 (USD Million)
Figure 11.14 Drug Repurposing Outsourcing Market in Europe, Base Scenario, 2020-2030 (USD Million)
Figure 11.15 Drug Repurposing Outsourcing Market in Asia Pacific, Base Scenario, 2020-2030 (USD Million)

Table 4.1 Drug Repurposing Service Providers: List of CROs
Table 4.2 Drug Repurposing Service Providers: List of Big Data/Analytics Service Providers
Table 4.3 Drug Repurposing Service Providers: List of Technology Providers
Table 4.4 Drug Repurposing Service Providers: Information related to Type of Drug Molecule
Table 5.1 Drug Repurposing Service Providers: List of Non-Profit Organizations
Table 5.2 Cures Within Reach: Organization Overview
Table 5.3 GlobalCures: Organization Overview
Table 5.4 Anticancer Fund: Organization Overview
Table 5.5 NCATS: Organization Overview
Table 5.6 Drug Repurposing Service Providers: List of Academic Organizations
Table 6.1 Auxiliis Pharma: Company Overview
Table 6.2 ChemBio Discovery Solutions: Company Overview
Table 6.3 GVK Bio: Company Overview
Table 6.4 GVK Bio: Future Outlook
Table 6.5 Iris Pharma: Company Overview
Table 6.6 Physiogenex: Company Overview
Table 6.7 Excelra: Company Overview
Table 6.8 Excelra: Future Outlook
Table 6.9 Smart Pharma: Company Overview
Table 6.10 Lantern Pharma: Company Overview
Table 6.11 Panxome: Company Overview
Table 6.12 Pharmacelera: Company Overview
Table 6.13 Socium: Company Overview
Table 6.14 SOM Biotech: Company Overview
Table 6.15 SOM Biotech: Future Outlook
Table 7.1 Drug Repurposing Service Providers: List of Partnerships, 2013-2020
Table 7.2 Drug Repurposing Service Providers: Information on Type of Technology/Platform and Therapeutic Area
Table 8.1 List of Drug Repurposing Initiatives of Big Pharma Players
Table 8.2 AbbVie: In-House Initiatives
Table 8.3 Astellas Pharma: Initiatives in Collaboration with Other Stakeholders
Table 8.4 Astellas Pharma: Recent Regulatory Approvals of Repurposed Drugs
Table 8.5 AstraZeneca: In-House Initiatives
Table 8.6 AstraZeneca: Initiatives in Collaboration with Other Stakeholders
Table 8.7 Bayer: Initiatives in Collaboration with Other Stakeholders
Table 8.8 Boehringer Ingelheim: Initiatives in Collaboration with Other Stakeholders
Table 8.9 Boehringer Ingelheim: Recent Regulatory Approvals of Repurposed Drugs
Table 8.10 Eli Lilly: Initiatives in Collaboration with Other Stakeholders
Table 8.11 Eli Lilly: Recent Regulatory Approvals of Repurposed Drugs
Table 8.12 Gilead Sciences: Recent Regulatory Approvals of Repurposed Drugs
Table 8.13 GSK: In-House Initiatives
Table 8.14 GSK: Initiatives in Collaboration with Other Stakeholders
Table 8.15 Novartis: In-House Initiatives
Table 8.16 Novartis: Initiatives in Collaboration with Other Stakeholders
Table 8.17 Novartis: Recent Regulatory Approvals of Repurposed Drugs
Table 8.18 Roche: In-House Initiatives
Table 8.19 Roche: Initiatives in Collaboration with Other Stakeholders
Table 8.20 Sanofi: In-House Initiatives
Table 8.21 Sanofi: Recent Regulatory Approvals of Repurposed Drugs
Table 8.22 Pfizer: Initiatives in Collaboration with Other Stakeholders
Table 9.1 List of Potential Drug Candidates
Table 10.1 Likely Cost Reduction for Repurposed Drugs
Table 15.1 Overall List of Potential Drug-Indication Candidates
Table 15.2 List of Potential Drug-Indication Candidates for Oncology Disorders
Table 15.3 List of Potential Drug-Indication Candidates for CNS Disorders
Table 15.4 List of Potential Drug-Indication Candidates for Metabolic Disorders
Table 15.5 List of Potential Drug-Indication Candidates for Infectious Disorders
Table 15.6 List of Potential Drug-Indication Candidates for Autoimmune Disorders
Table 17.1 Drug Repurposing Service Providers: Distribution by Company Type
Table 17.2 Drug Repurposing Service Providers: Distribution by Company Type, Year of Establishment and Location of Headquarters
Table 17.3 Drug Repurposing CROs: Distribution by Year of Establishment
Table 17.4 Drug Repurposing CROs: Distribution by Company Size
Table 17.5 Drug Repurposing CROs: Distribution by Location of Headquarters
Table 17.6 Drug Repurposing CROs: Distribution by Company Size and Location of Headquarters
Table 17.7 Drug Repurposing CROs: Distribution by Technology Specifications
Table 17.8 Drug Repurposing CROs: Distribution by Type of Drug Molecule
Table 17.9 Drug Repurposing CROs: Distribution by Status of Drug
Table 17.10 Drug Repurposing CROs: Distribution by Repurposing Approach
Table 17.11 Drug Repurposing CROs: Distribution by Type of Services Offered
Table 17.12 Drug Repurposing Big Data/Analytics Service Providers: Distribution by Year of Establishment
Table 17.13 Drug Repurposing Big Data/Analytics Service Providers: Distribution by Company Size
Table 17.14 Drug Repurposing Big Data/Analytics Service Providers: Distribution by Location of Headquarters
Table 17.15 Drug Repurposing Big Data/Analytics Service Providers: Distribution by Company Size and Location of Headquarters
Table 17.16 Drug Repurposing Big Data/Analytics Service Providers: Distribution by Technology Specifications
Table 17.17 Drug Repurposing Big Data/Analytics Service Providers: Distribution by Type of Drug Molecule
Table 17.18 Drug Repurposing Big Data/Analytics Service Providers: Distribution by Status of Drug
Table 17.19 Drug Repurposing Big Data/Analytics Service Providers: Distribution by Repurposing Approach
Table 17.20 Drug Repurposing Big Data/Analytics Service Providers: Distribution by Type of Services Offered
Table 17.21 Drug Repurposing Technology Providers: Distribution by Year of Establishment
Table 17.22 Drug Repurposing Technology Providers: Distribution by Company Size
Table 17.23 Drug Repurposing Technology Providers: Distribution by Location of Headquarters
Table 17.24 Drug Repurposing Technology Providers: Distribution by Company Size and Location of Headquarters
Table 17.25 Drug Repurposing Technology Providers: Distribution by Technology Specifications
Table 17.26 Drug Repurposing Technology Providers: Distribution by Type of Drug Molecule
Table 17.27 Drug Repurposing Technology Providers: Distribution by Status of Drug
Table 17.28 Drug Repurposing Technology Providers: Distribution by Repurposing Approach
Table 17.29 Drug Repurposing Technology Providers: Distribution by Type of Services Offered
Table 17.30 Drug Repurposing Service Providers: Cumulative Distribution by Year of Partnership Pre-2015-2020
Table 17.31 Drug Repurposing Service Providers: Distribution by Type of Partnership
Table 17.32 Drug Repurposing Service Providers: Distribution by Type of Technology/Platform Used
Table 17.33 Drug Repurposing Service Providers: Distribution by Therapeutic Area
Table 17.34 Drug Repurposing Service Providers: Country-wise Distribution
Table 17.35 Big Pharma Players: Distribution by Number of Drug Repurposing Initiatives, 2011-2020
Table 17.36 Big Pharma Players: Cumulative Distribution by Year of Initiative
Table 17.37 Big Pharma Players: Distribution by Type of Initiative
Table 17.38 Big Pharma Players: Distribution by Therapeutic Area
Table 17.39 Big Pharma Players: Distribution by Type of Drug Molecule
Table 17.40 Discontinued Clinical Trials: Distribution by Trial Status
Table 17.41 Discontinued Clinical Trials: Distribution by Trial Phase
Table 17.42 Discontinued Clinical Trials: Distribution by Cause of Discontinuation of Clinical Research
Table 17.43 Discontinued Clinical Trials: Distribution by Therapeutic Area
Table 17.44 Discontinued Clinical Trials: Distribution by Location of Trial Site
Table 17.45 Discontinued Clinical Trials: Distribution by Phase versus Cause of Discontinuation of Clinical Research
Table 17.46 Discontinued Clinical Trials: Distribution by Trial Status for Oncology Disorders
Table 17.47 Discontinued Clinical Trials: Distribution by Trial Phase for Oncology Disorders
Table 17.48 Discontinued Clinical Trials: Distribution by Cause of Discontinuation of Clinical Research for Oncology Disorders
Table 17.49 Discontinued Clinical Trials: Distribution by Location of Trial Site for Oncology Disorders
Table 17.50 Discontinued Clinical Trials: Distribution by Trial Status for CNS Disorders
Table 17.51 Discontinued Clinical Trials: Distribution by Trial Phase for CNS Disorders
Table 17.52 Discontinued Clinical Trials: Distribution by Cause of Discontinuation of Clinical Research for CNS Disorders
Table 17.53 Discontinued Clinical Trials: Distribution by Location of Trial Site for CNS Disorders
Table 17.54 Discontinued Clinical Trials: Distribution by Trial Status for Metabolic Disorders
Table 17.55 Discontinued Clinical Trials: Distribution by Trial Phase for Metabolic Disorders
Table 17.56 Discontinued Clinical Trials: Distribution by Cause of Discontinuation of Clinical Research for Metabolic Disorders
Table 17.57 Discontinued Clinical Trials: Distribution by Location of Trial Site for Metabolic Disorders
Table 17.58 Discontinued Clinical Trials: Distribution by Trial Status for Infectious Disorders
Table 17.59 Discontinued Clinical Trials: Distribution by Trial Phase for Infectious Disorders
Table 17.60 Discontinued Clinical Trials: Distribution by Cause of Discontinuation of Clinical Research for Infectious Disorders
Table 17.61 Discontinued Clinical Trials: Distribution by Location of Trial Site for Infectious Disorders
Table 17.62 Discontinued Clinical Trials: Distribution by Trial Status for Autoimmune Disorders
Table 17.63 Discontinued Clinical Trials: Distribution by Trial Phase for Autoimmune Disorders
Table 17.64 Discontinued Clinical Trials: Distribution by Cause of Discontinuation of Clinical Research for Autoimmune Disorders
Table 17.65 Discontinued Clinical Trials: Distribution by Location of Trial Site for Autoimmune Disorders
Table 17.66 Overall Cost Saving Potential of Repurposed Drugs, 2020-2030 (USD Billion)
Table 17.67 Overall Drug Repurposing Services Market, Base, Conservative, Optimistic Scenario, 2020-2030 (USD Million)
Table 17.68 Drug Repurposing Services Market: Distribution by Type of Drug Molecule, 2020-2030 (%)
Table 17.69 Drug Repurposing Services Market for Small Molecules, Base, Conservative, Optimistic Scenario, 2020-2030 (USD Million)
Table 17.70 Drug Repurposing Services Market for Biologics, Base, Conservative, Optimistic Scenario, 2020-2030 (USD Million)
Table 17.71 Drug Repurposing Services Market: Distribution by Therapeutic Area, 2020, 2025 and 2030 (%)
Table 17.72 Drug Repurposing Services Market for Same Therapeutic Area, Base, Conservative, Optimistic Scenario, 2020-2030 (USD Million)
Table 17.73 Drug Repurposing Services Market for Different Therapeutic Area, Base, Conservative, Optimistic Scenario, 2020-2030 (USD Million)
Table 17.74 Drug Repurposing Services Market: Distribution by Company Size, 2020-2030
Table 17.75 Drug Repurposing Services Market for Small Companies, Base, Conservative, Optimistic Scenario, 2020-2030 (USD Million)
Table 17.76 Drug Repurposing Outsourcing Market for Mid-Sized Companies, Base, Conservative, Optimistic Scenario, 2020-2030 (USD Million)
Table 17.77 Drug Repurposing Outsourcing Market for Large and Very Large Companies, Base, Conservative, Optimistic Scenario, 2020-2030 (USD Million)
Table 17.78 Drug Repurposing Outsourcing Market: Distribution by Geography, 2020, 2025 and 2030 (%)
Table 17.79 Drug Repurposing Outsourcing Market in North America, Base, Conservative, Optimistic Scenario, 2020-2030 (USD Million)
Table 17.80 Drug Repurposing Outsourcing Market in Europe, Base, Conservative, Optimistic Scenario, 2020-2030 (USD Million)
Table 17.81 Drug Repurposing Outsourcing Market in Asia Pacific, Base, Conservative, Optimistic Scenario, 2020-2030 (USD Million)